Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jan;55(1):439-42.
doi: 10.1128/AAC.00735-10. Epub 2010 Oct 11.

Inhibition of bacterial multidrug resistance by celecoxib, a cyclooxygenase-2 inhibitor

Arunasree M Kalle  1 , Arshad Rizvi
Affiliations

Inhibition of bacterial multidrug resistance by celecoxib, a cyclooxygenase-2 inhibitor

Arunasree M Kalle et al. Antimicrob Agents Chemother. 2011 Jan.

Abstract

Multidrug resistance (MDR) is a major problem in the treatment of infectious diseases and cancer. Accumulating evidence suggests that the cyclooxygenase-2 (COX-2)-specific inhibitor celecoxib would not only inhibit COX-2 but also help in the reversal of drug resistance in cancers by inhibiting the MDR1 efflux pump. Here, we demonstrate that celecoxib increases the sensitivity of bacteria to the antibiotics ampicillin, kanamycin, chloramphenicol, and ciprofloxacin by accumulating the drugs inside the cell, thus reversing MDR in bacteria.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Bar graphs showing the effects of celecoxib in combination with antibiotics (AMP, KAN, CHL, and CIP) on S. aureus (A), MRSA (B), and M. smegmatis (C).
FIG. 2.
FIG. 2.
Flow cytometry histograms showing EtBr accumulation in S. aureus (A), MRSA (B), and M. smegmatis (C) treated with antibiotics and celecoxib alone and in combination. Each panel (A, B, or C) has four histograms corresponding to treatments with four different antibiotics (AMP, KAN, CHL, and CIP).
See this image and copyright information in PMC

References

    1. Arunasree, K. M., K. R. Roy, K. Anilkumar, A. Aparna, G. V. Reddy, and P. Reddanna. 2008. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1. Leuk. Res. 32:855-864. - PubMed
    1. Danilchanka, O., C. Mailaender, and M. Niederweis. 2008. Identification of a novel multidrug efflux pump of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 52:2503-2511. - PMC - PubMed
    1. Gupta, A. K., D. S. Chauhan, K. Srivastava, R. Das, S. Batra, M. Mittal, P. Goswami, N. Singhal, V. D. Sharma, K. Venkatesan, S. E. Hasnain, and V. M. Katoch. 2006. Estimation of efflux mediated multi-drug resistance and its correlation with expression levels of two major efflux pumps in mycobacteria. J. Commun. Dis. 38:246-254. - PubMed
    1. Kalle, A. M., S. Sachchidanand, and R. Pallu. 2010. Bcr-Abl-independent mechanism of resistance to imatinib in K562 cells: induction of cyclooxygenase-2 (COX-2) by histone deacetylases (HDACs). Leuk. Res. 34:1132-1138. - PubMed
    1. Kern, W. V., P. Steinke, A. Schumacher, S. Schuster, H. von Baum, and J. A. Bohnert. 2006. Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Escherichia coli. J. Antimicrob. Chemother. 57:339-343. - PubMed

MeSH terms